Stereotaxis to Showcase Cutting-Edge Robotics Innovations
Stereotaxis (NYSE: STXS), a key player in advanced surgical robotics for minimally invasive procedures, has exciting news for investors and industry enthusiasts alike. David Fischel, the company's esteemed Chairman and CEO, is set to present at two significant investor conferences in the bustling environment of New York City, both scheduled for September.
About the Upcoming Conferences
The first conference, the H.C. Wainwright 27th Annual Global Investment Conference, takes place on Wednesday, September 10, 2025. At this event, Mr. Fischel will provide a comprehensive overview of Stereotaxis’ business innovations and growth prospects starting at 8:00 AM EDT. In addition to his presentation, he will be available for one-on-one meetings on the same day, offering a unique opportunity for personalized discussions with stakeholders interested in the company’s trajectory.
Second Event: Lake Street Capital Conference
Following this, on Thursday, September 11, 2025, Mr. Fischel will also participate in the Lake Street Capital 9th Annual Best Ideas Growth Conference. Similar to the first, he will engage in one-on-one meetings, allowing attendees to gain further insight into Stereotaxis’ strategic direction and innovative breakthroughs.
Excitement in Engineering Innovation
Mr. Fischel expressed enthusiasm regarding these engagements, stating, “We are excited to participate in these conferences and look forward to sharing the technological and commercial progress being made in Stereotaxis’ growth strategy.” This sentiment highlights the company's commitment to transparency and investor relations, providing a window into their forward-thinking advancements.
About Stereotaxis and Its Mission
Stereotaxis stands out as a pioneer in the field of surgical robotics. Their mission revolves around advancing the discovery, development, and delivery of robotic systems that enhance both patient care and procedural outcomes. With over 150,000 patients treated globally, Stereotaxis technology is revolutionizing the landscape of interventional procedures. By infusing precision and safety into the operations, they empower clinicians and contribute significantly to enhancing healthcare delivery.
In addition to their core focus on surgical robotics, Stereotaxis emphasizes a broader vision for healthcare technology. They aim to improve access to minimally invasive therapies, enhance surgical productivity, and foster better connectivity and intelligence in operating rooms. This holistic approach ensures that they are at the forefront of delivering cutting-edge solutions tailored to modern healthcare challenges.
Company Contacts for Investors
For those interested in further information or media inquiries, the leadership team at Stereotaxis is readily available. David L. Fischel serves as the Chairman and Chief Executive Officer, and Kimberly Peery acts as the Chief Financial Officer. Interested parties can reach out directly at 314-678-6100 or by emailing Investors@Stereotaxis.com.
Frequently Asked Questions
What is Stereotaxis known for?
Stereotaxis is recognized as a leader in surgical robotics for minimally invasive endovascular intervention.
Who will present at the conferences?
David Fischel, the Chairman and CEO of Stereotaxis, will present at the conferences.
When are the investor conferences scheduled?
The conferences are scheduled for September 10 and September 11, 2025.
What will be discussed at the conferences?
Topics will include Stereotaxis' business overview, technological advancements, and opportunities for one-on-one discussions.
How can investors contact Stereotaxis?
Investors can reach Stereotaxis via email at Investors@Stereotaxis.com or call 314-678-6100.
